Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

BAL THERAPY OF SEVERE PERIPHERAL NEUROPATHIES

BAL THERAPY OF SEVERE PERIPHERAL NEUROPATHIES Abstract IT IS the opinion of some neurologists that the neuropathies are initially biochemical disorders of the neuron, due chiefly to disruption of one or more enzyme systems that regulate the metabolism of the cell. According to this theory, the neuronal dysfunction that results can be severe but structural changes in the myelin or axon need not occur. Neurons in this stage of dysfunction should be able to recover rapidly over a period of hours or days if enzymatic equilibrium is restored. Anesthetics, such as procaine, are capable of producing analogous dysfunction and rapid recovery. Such rapid resolution of impaired conduction is inconsistent with recovery from structural changes in the neuron, which proceeds at a rate of from 0.5 to 2 mm. a day. When the disruption of cellular metabolism has reached an irreversible stage, degeneration of the neuron results, and recovery will follow the laws of regeneration. Dr. J. M. References 1. Peters, R. A.; Stocken, L. A., and Thompson, R. H. S.: British Anti-Lewisite (BAL) , Nature , London 156:616 ( (Nov. 24) ) 1945.Crossref 2. Waters, L. L., and Stock, C.: BAL (British Anti-Lewisite) , Science 102:601 ( (Dec. 14) ) 1945.Crossref 3. Longcope, W. T., and Luetscher, J. A.: The Treatment of Acute Mercury Poisoning by BAL , J. Clin. Investigation 25:557 ( (July) ) 1946.Crossref 4. Gilman, A.; Allen, R.; Philips, F. S., and St. John, E.: The Treatment of Acute Systemic Mercury Poisoning in Experimental Animals with BAL, Thiosorbital and BAL Glucoside , J. Clin. Investigation 25:549 ( (July) ) 1946.Crossref 5. Eagle, H.; Germuth, F. G.; Magnuson, H. J., and Fleishman, R.: Protective Action of BAL in Experimental Antimony Poisoning , J. Pharmacol. & Exper. Therap. 89:196 ( (Feb.) ) 1947. 6. Simon, F. P.; Potts, A. M., and Gerard, R. W.: Action of Cadmium and Thiols on Tissues and Enzymes , Arch. Biochem. 12:283 ( (Feb.) ) 1947. 7. Eagle, H.; Magnuson, H. J., and Fleishman, R.: The Systemic Treatment of Experimental Arsenic Poisoning (Mapharsen, Lewisite, Phenyl Arsenoxide) with BAL , J. Clin. Investigation 25:451 ( (July) ) 1946. 8. Barron, E. S.; Miller, Z. B.; Bartlett, G. B.; Meyer, J., and Singer, T. P.: Reactivation by Dithiols of Enzymes Inhibited by Lewisite , Biochem. J. 41:69 ( (Jan.) ) 1947. 9. Waters and Stock.1a 10. Footnote 1. 11. Eagle and others.5 12. Germuth, F. G., and Eagle, H.: The Efficacy of BAL (2,3-Dimercaptopropanol) in the Treatment of Experimental Lead Poisoning in Rabbits , J. Pharmacol. & Exper. Therap. 92:397 ( (April) ) 1948. 13. Barron and others.6 14. Barron, E. S.; Miller, Z. B., and Meyer, J.: The Effect of 2,3-Dimercaptopropanol on the Activity of Enzymes and on the Metabolism of Tissues , Biochem. J. 41:78 ( (Jan.) ) 1947. 15. Webb, E. C., and Van Heyningen, R.: The Action of British Anti-Lewisite (BAL) on Enzyme System , Biochem. J. 41:74, ( (Jan.) ) 1947. 16. This preparation contains 10 mg. of thiamine hydrochloride, 10 mg. of riboflavin, 5 mg. of pyridoxine hydrochloride, 50 mg. of calcium pantothenate and 250 mg. of nicotinamide in powder form for injection after proper solution has been effected. 17. Modell, W.; Gold, H., and Cattell, M.: Pharmacologic Observations on BAL by Intramuscular Injection in Man , J. Clin. Investigation 25:480 ( (July) ) 1946. 18. Sulzberger, M. B.; Baer, R. L., and Kanof, A.: Studies on the Toxicity of BAL on Percutaneous and Parenteral Administration , J. Clin. Investigation 25:474 ( (July) ) 1946. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Neurology & Psychiatry American Medical Association

BAL THERAPY OF SEVERE PERIPHERAL NEUROPATHIES

Archives of Neurology & Psychiatry , Volume 60 (3) – Sep 1, 1948

Loading next page...
 
/lp/american-medical-association/bal-therapy-of-severe-peripheral-neuropathies-Y3PE0uj0U0
Publisher
American Medical Association
Copyright
Copyright © 1948 American Medical Association. All Rights Reserved.
ISSN
0096-6754
DOI
10.1001/archneurpsyc.1948.02310030051004
Publisher site
See Article on Publisher Site

Abstract

Abstract IT IS the opinion of some neurologists that the neuropathies are initially biochemical disorders of the neuron, due chiefly to disruption of one or more enzyme systems that regulate the metabolism of the cell. According to this theory, the neuronal dysfunction that results can be severe but structural changes in the myelin or axon need not occur. Neurons in this stage of dysfunction should be able to recover rapidly over a period of hours or days if enzymatic equilibrium is restored. Anesthetics, such as procaine, are capable of producing analogous dysfunction and rapid recovery. Such rapid resolution of impaired conduction is inconsistent with recovery from structural changes in the neuron, which proceeds at a rate of from 0.5 to 2 mm. a day. When the disruption of cellular metabolism has reached an irreversible stage, degeneration of the neuron results, and recovery will follow the laws of regeneration. Dr. J. M. References 1. Peters, R. A.; Stocken, L. A., and Thompson, R. H. S.: British Anti-Lewisite (BAL) , Nature , London 156:616 ( (Nov. 24) ) 1945.Crossref 2. Waters, L. L., and Stock, C.: BAL (British Anti-Lewisite) , Science 102:601 ( (Dec. 14) ) 1945.Crossref 3. Longcope, W. T., and Luetscher, J. A.: The Treatment of Acute Mercury Poisoning by BAL , J. Clin. Investigation 25:557 ( (July) ) 1946.Crossref 4. Gilman, A.; Allen, R.; Philips, F. S., and St. John, E.: The Treatment of Acute Systemic Mercury Poisoning in Experimental Animals with BAL, Thiosorbital and BAL Glucoside , J. Clin. Investigation 25:549 ( (July) ) 1946.Crossref 5. Eagle, H.; Germuth, F. G.; Magnuson, H. J., and Fleishman, R.: Protective Action of BAL in Experimental Antimony Poisoning , J. Pharmacol. & Exper. Therap. 89:196 ( (Feb.) ) 1947. 6. Simon, F. P.; Potts, A. M., and Gerard, R. W.: Action of Cadmium and Thiols on Tissues and Enzymes , Arch. Biochem. 12:283 ( (Feb.) ) 1947. 7. Eagle, H.; Magnuson, H. J., and Fleishman, R.: The Systemic Treatment of Experimental Arsenic Poisoning (Mapharsen, Lewisite, Phenyl Arsenoxide) with BAL , J. Clin. Investigation 25:451 ( (July) ) 1946. 8. Barron, E. S.; Miller, Z. B.; Bartlett, G. B.; Meyer, J., and Singer, T. P.: Reactivation by Dithiols of Enzymes Inhibited by Lewisite , Biochem. J. 41:69 ( (Jan.) ) 1947. 9. Waters and Stock.1a 10. Footnote 1. 11. Eagle and others.5 12. Germuth, F. G., and Eagle, H.: The Efficacy of BAL (2,3-Dimercaptopropanol) in the Treatment of Experimental Lead Poisoning in Rabbits , J. Pharmacol. & Exper. Therap. 92:397 ( (April) ) 1948. 13. Barron and others.6 14. Barron, E. S.; Miller, Z. B., and Meyer, J.: The Effect of 2,3-Dimercaptopropanol on the Activity of Enzymes and on the Metabolism of Tissues , Biochem. J. 41:78 ( (Jan.) ) 1947. 15. Webb, E. C., and Van Heyningen, R.: The Action of British Anti-Lewisite (BAL) on Enzyme System , Biochem. J. 41:74, ( (Jan.) ) 1947. 16. This preparation contains 10 mg. of thiamine hydrochloride, 10 mg. of riboflavin, 5 mg. of pyridoxine hydrochloride, 50 mg. of calcium pantothenate and 250 mg. of nicotinamide in powder form for injection after proper solution has been effected. 17. Modell, W.; Gold, H., and Cattell, M.: Pharmacologic Observations on BAL by Intramuscular Injection in Man , J. Clin. Investigation 25:480 ( (July) ) 1946. 18. Sulzberger, M. B.; Baer, R. L., and Kanof, A.: Studies on the Toxicity of BAL on Percutaneous and Parenteral Administration , J. Clin. Investigation 25:474 ( (July) ) 1946.

Journal

Archives of Neurology & PsychiatryAmerican Medical Association

Published: Sep 1, 1948

References